Dupont Pharmaceutical studies have demonstrated the efficacy of efavirenz with AZT and 3TC in treatment-naive patients. When compared to a protease inhibitor regimen, 95 percent of the patients taking the efavirenz combination achieved a viral load of less than 400 copies/ml at 24 weeks. Abacavir is also attracting attention due to its potency and dosing convenience. Abacavir has contributed to lower viral loads in treatment naive patients when combined with ZDV and 3TC. Both efavirenz and abacavir should be available in the Fall.
|Original language||English (US)|
|Number of pages||1|
|Journal||The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service|
|State||Published - Sep 1998|
ASJC Scopus subject areas